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HLA DQ region gene polymorphism associated with primary IgA
nephropathy. IgA nephropathy (IgAN) has been associated with HLA-
DR4. We have recently described two non-allelic Taq I DQ/3 gene-
associated fragments sized 2.0 kb (T2) and 6.0 kb (T6), which strongly
associate with DR4. T2 represents a polymorphism of the DQ/3 gene
and has been redesignated DQw8 (10th International HLA Workshop).
The origin of the T6 fragment has not been determined, but probably
represents a polymorphism of either the DQ or DXI3 gene. When
present together T2 and T6 define a subgroup of DR4 subjects at high
risk of developing autoimmune disease. We have, therefore, studied
DQ/3 gene polymorphisms in IgAN. The DR antigen distribution was
similar in IgAN and normal controls. The T2+/T6+ phenotype was
present in 49% patients with IgAN compared to 15% of controls [P <
0.0001, y 32.8, Cramer's V = 0.41; relative risk = 5.5 (range,
2.8—11.0)]. Seventy-two percent of DR4+ IgAN patients and 29% of
DR4+ controls were T2+1T6+ (P = 0.007, = 17.0). These findings
confirm the hypothesis that disease susceptibility genes are important in
IgAN, and suggest that the putative gene(s) are located within or near
to the DQ subregion. Moreover, similar DQf3 gene associations have
been found in IDDM and pemphigus vulgaris, pointing to a common
immunogenetic mechanism predisposing to several autoimmune dis-
eases.
IgA nephropathy [IgAN] is one of the commonest forms of
primary glomerular disease, and may lead to end-stage renal
failure in a significant proportion of patients [1]. The immuno-
pathogenesis remains unclear, but much clinical and experi-
mental evidence point to an immune complex mediated process
[1, 2]. In particular, impaired regulation of IgA production
appears to be important, and several features suggest that an
underlying genetically mediated abnormality of the IgA immune
response is responsible.
First, abnormalities of IgA production may be demonstrated
not only in patients with IgAN, but also in healthy family
members [3]. Secondly, familial cases of IgAN occurring in
siblings and parent-child pairs have been described by several
authors [3]. Thirdly, IgAN has been described secondary to
several immunological diseases which are noted to have asso-
cations with HLA determinants: seronegative spondyloarthrop-
athies, rheumatoid arthritis, coeliac disease and dermatitis
herpetiformis [4]. Finally, family and population studies of
patients with IgAN have revealed an association with certain
serologically-defined HLA antigens [reviewed in 1, 3, 5]. Early
studies noted an association with Bl2 and Bw35, but recently
an increased frequency of DR4 has been found in France and
Japan, and of DR1 in Britain. However, others have not been
able to demonstrate an association with either HLA Class I or
II antigens [3]. The inconsistency of these observations sug-
gests that the genes encoding the HLA determinants are not
those conferring disease susceptibility, but are markers for a
closely linked disease susceptibility gene. The most frequently
noted associations have been with HLA Class II molecules
which indicates that the putative gene[s] may reside within the
HLA-D region on chromosome 6.
The advent of recombinant DNA technology has greatly
facilitated the search for HLA-associated disease susceptibility
genes. Until recently, analysis of the major histocompatibility
complex (MHC) has been confined to the detection of serolog-
ically-defined antigenic determinants, but analysis at the ge-
nomic level has defined additional heterogeneity within sero-
logical specificities. The HLA Class II region genes are situated
within the MHC on the short arm of chromosome 6, and are
arranged in three main subregions: DR, DQ, and DP. Each class
II molecule consists of non-covalently linked a and /3 chains.
The DR locus consists of one a chain gene and three /3 chain
genes. The DQ subregion consists of a single a and /3 chain gene
at both the DQ and DX loci, while the DP region has two a and
/3 chain genes. All of these genes have been shown to be
polymorphic. Thus, investigation of restriction fragment length
polymorphisms (RFLPs) using Southern blot analysis and DNA
hybridisation techniques has provided a useful tool to investi-
gate disease susceptibility genes located within the HLA-D
region.
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Recently, RFLPs of the DR, DQ, and DP genes have been
identified which segregate with several autoimmune diseases
[6—15]. Indeed, in insulin-dependent diabetes mellitus (IDDM)
current evidence suggests that one of the genes involved in the
disease is located within the HLA-DQ subregions [6—11, 16, 17].
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We have previously demonstrated two Taq I fragments de-
tected by a DQI3 gene probe, sized 2.0 kb and 6.0 kb (designated
T2 and T6, respectively), which when inherited together define
a subgroup of subjects with DR4 at increased risk of IDDM [10,
11]. Furthermore, DQI3T2 is also associated with DR7 and
DQ/3T6 with DR1. Population studies of IgAN have been
confined previously to analysis of serologically-defined HLA
determinants. We have, therefore, used DNA hydndization
techniques to examine the distribution of DR4 and DR1 asso-
ciated DQ/3 chain RFLPs in British Caucasoid patients and
controls, in order to examine more precisely the HLA associ-
ations in IgAN.
Methods
Patients and controls
All the subjects studied were unrelated British Caucasoids.
Patients. One hundred and four patients with biopsy-proven
primary IgAN and with no clinical or serological evidence of
Henoch-Schönlein purpura, systemic lupus erythematosus, al-
coholic liver disease, or other immunological diseases with
recognized associations with IgAN [4] were recruited from the
Renal Units at The London, St Philip's, and St Thomas'
Hospitals, London, and the Freeman Hospital, and the Royal
Victoria Infirmary, Newcastle. The clinical features of this
group were as follows: 78% male, 35% had impaired renal
function at the time of investigation (creatinine > 125 moII
liter), and 19% presented with macroscopic hematuria.
Patient controls. Blood was collected from 46 patients with
another type of immune-mediated primary glomerulonephritis,
idiopathic membranous nephropathy (IMN), to act as a patient
control group. These patients had no clinical, serological, or
biochemical evidence of diseases, infections, or drugs known to
be associated with membranous nephropathy. Seventy-eight
percent were male, and 61% had impaired renal function at the
time of investigation (creatinine > 125 moIIliter).
Healthy controls. One hundred and forty-nine healthy sub-
jects (53% male) with no history of renal disease were serially
recruited from academic staff and laboratory personnel at The
London Hospital Medical College.
DNA analysis
DNA from 238 subjects (94 controls, 46 patients with IMN,
and 98 patients wtih IgAN) was studied by Southern blot
techniques as previously described [9]. DNA was extracted, by
a modification of the method of Kunkel, from leukocytes
obtained from whole blood samples anticoagulated with EDTA,
and previously stored at —20°C. After digestion for 16 hours
with the restriction enzyme Taq 1 (Anglian Biotechnology Ltd,
Colchester, UK), DNA fragments were separated by size by
electrophoresis on a 0.85% agarose gel and then transferred to
a nylon membrane (Gene Screen Plus; New England Nuclear
Research Products, Boston, USA) using an alkaline solvent by
the method of Southern. The filters were hybridized to a nick
translated 32P-labelled DQj3 gene probe [ref 18; Ava 1 insert of
pDR-131 sized 0.6 kb] according to standard protocol (New
England Nuclear). All filters were washed down to a high
stringency (0.1 x SSC) and visualized by autoradiography using
Kodak XAR5 film in the presence of two, high-speed intensify-
ing screens for 36 hours at —70°C (Eastman Kodak, Rochester,
Table 1. Frequency of HLA-DR antigens in IgAN and healthy
controls
DR
Specificity
Controls
N=149 IgANN=73
%
DRI 19.5 20.5
DR2 30.9 26.0
DR3 26.2 19.2
DR4 36.9 43.8
DR5° 18.8 17.9
DRW6b 17.5 20.6
DR7 31.5 21.9
DRw8 4.0 0
DR9 1.3 0
DRwIO 0.7 1.4
All comparisons of DR types between IgAN and healthy controls: NS
a Includes splits of DR5 (DRw1 I and DRwI2)b Includes splits of DRw6 (DRwI3 and DRw14)
New York, USA). Hybridization bands were sized by compar-
ison with an internal control (MJN genomic DNA) and Hind III
digested lambda phage (Bethesda Research Laboratories, Pais-
ley, Scotland, UK) present on each filter. MJN genomic DNA
allowed standardization of sizes of alleles between autoradio-
grams and also acted as an internal control for the presence of
T2 and T6. Individuals were scored for the presence (+) or
absence (—) ofT2 and T6, and the frequency distribution of the
T2/T6 phenotypic combinations (T2+/T6+, T2+/T6—, T2—/
T6+, T2—1T6—) was compared in the different study groups.
HLA typing
Tissue typing for HLA-DR antigens was performed by stan-
dard serological techniques. Seventy-three patients with IgAN
were DR typed, and the frequency distribution was compared
to the healthy controls.
Statistical methods
Serological and RFLP data were analyzed by the chi-square
test using appropriate sized contingency tables, and Yates'
correction. The relative risk and 95% confidence intervals were
calculated by the method of Woolf [19].
Results
The frequency of the DR antigens in patients with IgAN was
not significantly different from the distribution in the healthy
controls (Table 1). In particular, the phenotypic frequency of
DR4 in IgAN and normal controls was 43.8% and 36.9%,
respectively, and for DR1 was 20.5% and 19.5%, respectively.
Hybridization of the DQ/3 cDNA probe with Taq 1-digested
genomic DNA produced several gene-related fragments (Fig.
1). We have previously identified two polymorphic fragments
sized 2.0 kb (T2) and 6.0 kb (T6), and shown them to associate
with DR4 [10, 11]. T2 and T6 are non-allelic and can be
inherited together, separately, or not at all. The distribution of
the four possible DQf3 T2/T6 combinations is given in Table 2.
T2 and T6 were present together (T2+/T6+) more frequently in
patients with IgAN (49%) than in patient controls with IMN
(17%; P <0.0001, 2 = 32.6; Cramer's V = 0.48), and healthy
controls (15%; P < 0.0001, = 32.8; Cramer's V = 0.41); the
frequency of T2+1T6— and T2—/T6+ was not increased. The
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Table 2. Distribution of DQ T2 and T6 combinations
controls, IMN, IgAN and IDDM
in healthy
Group N
T2+/T6+ T2+/T6— T2—/T6+ T2—/T6—
%
Control
IMN
IgANb
IDDMC
94
46
98
66
15 21 27
17 4 30
49 17 24
53 12 15
37
48
10
20
Comparison between groups was made by chi-square test using
4 x 2 contingency tables with the Yates' correction.
a IMN vs. controls; NS
' IgAN vs. controls; P < 0.0001, = 32.8; Cramer's V = 0.41
Most subjects studied previously [II]: IDDM vs. controls; P =
0.0001, = 26.6, Cramer's V = 0.4
T2+1T6+ phenotype carries a relative risk of 5.5 (2.8 to 11.0)
compared to healthy controls. To determine if T2+/T6+ was
associated with clinical expression of disease the IgAN patients
were divided into subgroups; there was no relationship of the
DQ/3 RFLPs with patient sex, renal impairment, or macro-
scopic hematuria (data not shown).
DNA was available, allowing DQf3 DNA typing, in 63 pa-
tients with IgAN who had been serologically DR typed. The
frequency distribution of the DR antigens and the DQ/3 T2 and
T6 combinations in these patients was similar to the whole
group. Twenty-nine IgAN patients were DR4+, all but one of
whom possessed T2 and/or T6 (Table 3); of these, 72.5% were
Table 3. Distribution of DQ/3 T2 and T6 combinations in DR4+
healthy controls and IgAN
Group N
T2+/T6+ T2+/T6— T2—1T6+ T2—/T6—
%
Control 38 29 26 19 26
IgANa 29 72 3 21 4
Comparison between the two groups was made by the chi-square test
using a 4 x 2 contingency table with the Yates' correction.
aP = 0.001, x2 = 20.75, Cramer's V = 0.49
T2+1T6+. The T2/T6 positive phenotype was significantly
increased compared to the 38 DR4+ healthy controls (29%, P
0.007, = 17.0, Cramer's V = 0.50). Thirty-four IgAN patients
were DR4 negative; 38% were T2+/T6+ compared to 4% of 50
DR4 negative healthy controls (P = 0.001, y2 = 20.75, Cramer's
V = 0.49).
Discussion
We were unable to document an association of IgAN with
any of the serologically defined HLA-DR antigens. In particu-
lar, we cannot confirm an association with DR1, as seen in
Britain, or DR4, as reported in the French and Japanese
[reviewed in 1, 3, 5]. The patients in our study were recruited
from London and Newcastle, but the frequency distribution of
DR antigens in the reference control panels and in the patients
from the two centers is similar [20], and thus, a regional genetic
difference is unlikely to account for this observation.
The principal finding to emerge from these experiments was a
strong association of RFLPs of the DQf3 region in patients with
IgAN. A similar association was not found in the patient control
group with IMN. The latter is also an immune complex medi-
ated primary glomerular disease which segregates closely with
HLA-DR3 in Europeans [21], and, therefore, this DQI3 associ-
ation is likely to be specific for IgAN rather than a genetic
marker for glomerulonephritis. In IgAN, a significant increase
in the frequency of both the 2.0 kb (T2) and 6.0 kb (T6) DQf3
related fragments was seen. Furthermore, the phenotype T2+/
T6+ clearly associated with DR4 in patients with IgAN con-
firming our previous observations that the presence of T2 and
T6 in the same individual defines a subgroup of DR4 subjects
[10, 11]. These results may also explain the heterogeneous DR
associations with IgAN, DR1 in Britain and DR4 elsewhere, as
T6 also segregates with DR1 [11].
An increasing number of immunologically mediated diseases
appear to be linked to HLA-DR antigens, and evidence suggests
that products of the HLA Class II genes determine immune
responsiveness. The Class II molecules are transmembrane
glycoproteins composed of an a and a 13 sub-unit which are
expressed on the surface of B lymphocytes, macrophages/
monocytes, and some T lymphocytes [22], and are intimately
involved in antigen presentation. Foreign antigen peptide frag-
ments complexed with specific polymorphic residues of an
MHC Class II molecule interact with the T cell receptor leading
to antigen recognition and helper T-cell activation [23]. Thus,
the Class II products are integral components of the cellular and
humoral arms of the immune reaction. The IgA antibody
response is T-cell dependent [24], and, therefore, the DQI3
association could be of pathogenetic significance as it may be
T6 —
Fig. 1. DQI3 gene related fragments. Autoradiogram of RFLPs ob-
tained by Taq 1 digestion and hybridization with 32P-labelled cDNA
DQI3 probe of DNA obtained from 6 subjects. The subject in lane 2 is
positive for the 2.0 kb [T2] fragment [T2+] and also the 6.0 kb [T6}
fragment [T6+].
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postulated that polymorphisms of the DQ/3 chain may deter-
mine the responder status to antigens, either self or non-self.
Indeed, several autoimmune diseases have recently been linked
to RFLPs and sequence variations of the DQ/3 chain gene;
insulin dependent diabetes mellitus (IDDM) [6—8, 10, 11] rheu-
matoid arthritis (RA) [8, 10, 13] myasthenia gravis [12], and
pemphigus vulgaris [15]. It is relevant, therefore, that although
it has been generally accepted that an abnormal IgA response to
exogenous antigens might be of central importance in IgAN [1,
2], there is accumulating data to suggest that autoimmunity
plays a significant role. Namely, circulating IgA antibodies to
nuclear antigens [25], ssDNA [26], IgG [27], and glomerular
components [26, 28], have been described, and recently IgG
glomerular autoantibodies have been reported [291.
We have observed the same pattern of DQI3 T2+/T6+
frequency distribution in patients with IgAN as we have previ-
ously noted in IDDM (Table 2) [10, 11] and thus, IgAN and
IDDM appear to share the same DQ/3 gene association for
susceptibility to disease. However, IgAN and IDDM differ in
that IDDM, unlike IgAN, is also linked to DR3. Other groups
have examined RFLPs of the DQI3 gene in autoimmune dis-
eases, but different terminologies have been used. The DQw3.1
and DQw3.2 alleles, redesignated DQw7 and DQw8 respec-
tively at the 10th International HLA Workshop, in particular,
have been shown to positively associate with DR4 individuals
with RA [DQw3.1; ref 13] or IDDM [DQw3.2; ref 81. Reactivity
with the DQ monoclonal antibody designated TA1O enables
subjects to be distinguished who are either DQw3. 1 (TA 10
positive) or DQw3.2 (TAIO negative) [30]. In our studies, the
presence of T2 strongly correlated with TA1O negativity [10,111.
Thus, T2 and DQw.3.2 (DQw8) appear to be equivalent poly-
morphisms of the DQ3 gene, which is of immediate relevance to
our findings in IgAN. Todd and colleagues have sequenced
DQI3 alleles from haplotypes positively associated with IDDM
(including DQw3.2), and neutral to or protective against IDDM
(including DQw3. 1), and found that susceptibility to IDDM was
associated with a non-aspartate amino acid at residue 57 of the
DQI3 molecule [16]. A possible mechanism by which this
observation might be important has come from a recent under-
standing of the three dimensional structure of the HLA Class II
molecule [311. The antigen binding site has been identified, and
is composed of two a helices on top of a /3 pleated sheet. The
two a helices form a groove (Bjorkman's groove) which acts as
the peptide binding site; one a helix is derived from the
polymorphic domain of the DQ/3 chain and the other from the
polymorphic domain of the DQa chain. Position 57 is located at
one end of Bjorkman's groove, and Todd and colleagues have
postulated that susceptibility to IDDM may be accounted for by
DQ/3 polymorphism accompanied by additional amino acid
variation in the DQa chain, leading to impairment of peptide
binding to Bjorkman's groove and, thus, interfering with anti-
gen recognition by the T cell receptor [32]. However, since
IgAN has the same DQ/3 association as IDDM, a similar model
for genetic susceptibility to IgAN could be proposed, although
other susceptibility haplotypes to IgAN have not been identified
as yet. Taken together, our observations and Todd's hypothe-
sis, suggest that DQ/3 polymorphism may be a common mech-
anism in determining susceptibility to several autoimmune
diseases rather than to IDDM specifically. Indeed, the recent
observation that amino acid variation at position 57 in the DQ/3
molecule is also important in pemphigus vulgaris [15] supports
this argument. The identity of the T6 fragment is uncertain, but
the strength of the hybridization signal suggests that it probably
represents a polymorphism of the DQJ3 or DX/3 gene rather than
cross hybridization with the DRI3 or DP/3 genes.
Finally, the association of T2+/T6+ with IgAN is not com-
plete; 51% of patients with IgAN were T2—/T6— and 15% of
healthy controls were T2+/T6+. Thus, although T2+/T6+ is a
marker for disease susceptibility, it is not necessarily an etio-
logical locus. Nevertheless, the strength of the association
suggests that the DQ region might influence susceptibility to
IgAN. Furthermore, since similar DQf3 associations have been
reported in other autoimmune diseases it is likely that other
gene(s) either within, or outside, the MHC, or interaction with
specific environmental antigens are important in determining
clinical disease expression.
In conclusion, we have observed a close association of
RFLPs of the DQ region in British Caucasoid subjects with
IgAN. These findings explain the previously noted heteroge-
nous associations with HLA-DR antigens, and confirm the
hypothesis that a genetically mediated abnormality of the
immune response plays a central role in the development of
IgAN. Moreover, the gene(s) determining susceptibility appear
to be located within or adjacent to the DQ/3 locus. The DQ/3
region association may be important in understanding the
immunopathogenesis of IgAN. Recent evidence suggests that
autoimmunity is a significant feature in IgAN. Similar DQJ3
associations have been noted in several autoimmune diseases
pointing to a common immunogenetic mechanism shared with
IgAN.
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